Doubled dosage of sofosbuviris expected for inhbiting Zika virus infection

Publication date: Available online 15 June 2017 Source:Asian Pacific Journal of Tropical Medicine Author(s): Somsri Wiwanitkit, Viroj Wiwanitkit Sofosbuvir is a new antiviral drug that has been recommended for management of hepatitis C virus (HCV) for a few years. New researches support that sofosbuvir might be useful for the management of Zika virus infection. Based on the pharmacological activity, inhibiting the HCV RNA-dependent RNA polymerase (RdRp or NS5 protein), sofosbuvir is proposed for its effectiveness against Zika virus infection. Here, the authors used a mathematical modelling theoretical approach to predict the expected dosage of sofosbuvir for inhbiting Zika virus infection. Based on the modeling study, if sofosbuvir is assigned for management of Zika virus infection, doubled dosage of the present dosage for hepatitis C management is recommended.
Source: Asian Pacific Journal of Tropical Medicine - Category: Tropical Medicine Source Type: research